Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

Also called NCT07045142

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07045142
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07045142. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-01 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
Condition
Schizophrenia
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Lead sponsor
Central South University (class: other)
Collaborator
Zhumadian Second People's Hospital (class: not stated)
Collaborator
Changsha Third Hospital (class: other)
Collaborator
The Second People's Hospital of Dali Bai Autonomous Prefecture (class: not stated)
Collaborator
Xiangshan County Traditional Chinese Medicine Hospital Medical and Health Group Three Hospitals Distric (class: not stated)
Collaborator
Yueyang Rehabilitation Hospital (class: not stated)
Collaborator
Junshan District Psychiatric Rehabilitation Hospital (class: not stated)
Collaborator
The Second People's Hospital of Xiangyin County (class: not stated)

Record details

Record id
cardio:ct-nct07045142
Content hash
f27f2fbb371e6892c640dfc8060d013a3c561a0539911410ce34fe639604a0db